**Geoffrey D. Barnes, MD, MSc, FACC**
**Associate Professor**
University of Michigan

**Printed as of 11/20/2026**

# Disclosures

## Personal Commercial (10)

| Company Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria | Modest (< $5,000) | *Vascular Medicine* |
| Blue Cross Blue Shield of Michigan | Research/Research Grants | Significant (>= $5,000) | *Vascular Medicine* |
| Boston Scientific | Consultant Fees/Honoraria | Significant (>= $5,000) | *Vascular Medicine* |
| Boston Scientific | Research/Research Grants | Significant (>= $5,000) | *Pulmonary Hypertension and Venous Thromboembolic* |
| Bristol-Myers Squibb Company | Consultant Fees/Honoraria | Significant (>= $5,000) | *Vascular Medicine* |
| Dr. Reddy's Laboratories Inc. | Other - *Honorarium for CME* | Modest (< $5,000) | *Vascular Medicine* |
| Janssen Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= $5,000) | *Pulmonary Hypertension and Venous Thromboembolic* |
| Novartis Corporation | Consultant Fees/Honoraria | Significant (>= $5,000) | *Vascular Medicine* |
| Pfizer Inc | Consultant Fees/Honoraria | Significant (>= $5,000) | *Vascular Medicine* |
| Regeneron | Consultant Fees/Honoraria | Modest (< $5,000) | *Vascular Medicine* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| Anticoagulation Forum | Officer, Director, Trustee, or other Fiduciary Role | None ($0) | *Other* |

## Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|---|---|
| HI-PEITHO | Boston Scientific | |

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

**Certified Education Attestation** | Signed on 6/1/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 6/1/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 6/1/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

**On-Going Obligation Agreement** | Signed on 6/1/2026

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.